Interview with Richard Blackburn, Managing Director, Pfizer UK
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Address: Servier Laboratories Ltd, Wexham Springs, Framewood Rd, Wexham, Slough, Berkshire, SL3 6RJ, United Kingdom
Tel: +44 (0) 1753 662 744
Web: http://www.servier.co.uk/
Servier Laboratories Limited is the UK subsidiary of The Servier Research Group, a research-based pharmaceutical company specialising in innovative pharmaceuticals. Servier UK offers a range of products in a number of medical areas: cardiovascular disease, especially hypertension and cardiac disease, diabetes, osteoporosis and diseases of the central nervous system. Servier develops truly innovative drugs and invests in therapeutic areas where there is an unmet patient need.
COMMERCIAL:
Servier UK consists of Sales and Marketing departments which promote Servier’s portfolio of ethical pharmaceutical products to healthcare professionals.
R&D:
The Research and Development Division’s mission is to discover innovative active molecules and to present them in the form of drugs for purposes of meeting health needs in therapeutic domains where the company has scientific and medical expertise.
The International Centre for Therapeutic Research manages: Phase I, II and III clinical trials throughout the UK and the Republic of Ireland. It is also involved in the global development of diabetes compounds.
The Centre for Biopharmacy Research specialises in drug metabolism, pharmacokinetics and analytical chemistry.
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
